The Mounjaro Investigation: What the Evidence Actually Shows

What the clinical investigation actually set out to answer

The SURMOUNT programme was designed to answer a precise question: does tirzepatide produce meaningful, sustained weight loss in adults with obesity, and at what cost in side effects? SURMOUNT-1, the flagship trial, ran for 72 weeks and enrolled 2,539 adults without diabetes. Participants received either tirzepatide at 5, 10, or 15 mg, or a placebo, alongside guidance on diet and physical activity. The results, published in the New England Journal of Medicine, showed average body-weight reduction of around 20 to 21 percent at the 15 mg dose. That figure is not a best-case cherry-pick; it is the trial average across participants who completed the study.

A later head-to-head trial, SURMOUNT-5, put tirzepatide directly against semaglutide 2.4 mg in adults with obesity and no diabetes, running for 72 weeks. Tirzepatide produced greater average weight reduction. NICE cited this evidence in its appraisal of tirzepatide, published as TA1026 in December 2024, concluding that the medicine represented a cost-effective use of NHS resources for eligible adults. That independent committee review is itself a form of investigation: NICE scrutinises trial methodology, looks for industry bias, and stress-tests the numbers before recommending a medicine.

For anyone trying to decide whether to pursue treatment, the trial record matters because it is the foundation on which clinical suitability is assessed. It is also why Mounjaro cannot be bought freely; the clinical assessment is the mechanism through which that evidence is translated into an individual decision. If you want background on how the medicine came to exist in the first place, the history of Mounjaro's development covers the research path that led to licensing, and you can read more about when Mounjaro was invented and the timeline that brought it from early research to an approved treatment.

What the safety investigation found, and what it means in practice

Safety surveillance does not end when a medicine is licensed. Tirzepatide carries a Black Triangle (▼) designation in the UK, which means the MHRA continues to collect additional data on its effects in real-world use. This is standard for newer medicines and is not a cause for alarm; it is how the regulator maintains oversight beyond the trial setting.

The most significant recent safety communication came in January 2026, when the MHRA issued a Drug Safety Update covering GLP-1 medicines as a class. The update confirmed acute pancreatitis as a known but infrequent risk. The practical signal to watch for is severe abdominal pain that radiates toward the back, with or without vomiting, which warrants urgent medical attention. The MHRA's Yellow Card scheme allows patients to report any suspected side effect directly, and doing so actively contributes to ongoing safety monitoring.

The side-effect profile documented in the trials is mostly gastrointestinal: nausea, loose stools, indigestion, burping, constipation. For most people these are most noticeable in the first weeks after starting or after a dose increase, and they settle. Indigestion on Mounjaro is one of the questions our prescribers hear regularly, and there are practical measures that reduce its impact. What the safety investigation did not find was a signal that made regulators reconsider the medicine's overall approval; the MHRA's conclusion, like NICE's, was that benefits outweigh risks for the people the medicine is licensed for.

The NHS patient-level guide to tirzepatide on NHS.uk sets out the side effects, interactions and contraindications that any prescriber works through before approving treatment. It is worth reading before any consultation.

Who the evidence supports, and where the clinical decision sits

Understanding the investigation's findings is one thing; understanding whether they apply to you is another. The licence covers adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, such as high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone is not the whole picture: contraindications include a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and certain other conditions that the prescriber works through individually. Pregnancy, breastfeeding, and trying to conceive are also situations where Mounjaro is not recommended.

If you take oral contraceptives, the clinical guidance is specific: add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because gastric-emptying changes may reduce pill absorption. Women using HRT might consider switching to a transdermal preparation for similar reasons, which is worth raising with your GP.

Timing is worth mentioning here. If you are thinking about starting before a holiday or around a busy stretch at work, the adjustment period in the first few weeks is real; building in some flexibility helps. For a fuller picture of eligibility, prescribing criteria and what the full Mounjaro treatment pathway looks like, that page covers the practical detail. You can also read about how tirzepatide works as a molecule on the tirzepatide overview page.

Making sense of the decision: what the investigation means for you

The evidence base for Mounjaro is strong by any reasonable standard. Two regulatory bodies have reviewed it independently, a head-to-head trial against the leading alternative has been published, and post-marketing surveillance is active. What it does not do is answer the individual question — whether you, with your health history, current medicines, and personal circumstances, are a good candidate for this treatment. That is a clinical judgement, and it is the one a prescriber makes.

Private access through a GPhC-registered online pharmacy means that clinical assessment does not require a GP referral or a waiting list. At nume, a real prescriber reads your consultation the same day; it is not automated. The process includes photo-ID verification, live weight confirmation on video, and a check of your medical history before anything is approved. If approved, treatment is dispatched the same day for tracked next-working-day delivery. There are no subscriptions and every repeat is reviewed again from scratch.

For context on what private treatment costs and what the price covers, the weight-loss treatment overview lays that out plainly. And if you want to explore whether you are likely to be suitable, the Mounjaro page covers the full eligibility picture alongside the clinical team who reviews applications, including our lead prescriber.

If you are ready to take the next step, start your free consultation and a prescriber will review your case the same day.